Dextromethorphan-Bupropion (Auvelity)

Dextromethorphan-bupropion — marketed as Auvelity — is one of the more clever recent additions to antidepressant pharmacology. It is the first oral rapid-acting antidepressant, and the design is essentially a deliberate exploitation of a drug interaction to keep dextromethorphan around long enough to work as an NMDA antagonist.

The mechanism takes some unpacking. Dextromethorphan — yes, the cough suppressant — has substantial NMDA antagonist activity at high enough plasma levels. The problem is that dextromethorphan is rapidly metabolized by CYP2D6 to dextrorphan, which has weak NMDA activity. Given alone, dextromethorphan never reaches plasma levels sufficient for antidepressant NMDA blockade in most patients.

Bupropion is a potent CYP2D6 inhibitor. Combined with dextromethorphan, it slows the metabolism enough that dextromethorphan plasma levels rise into the therapeutic range. Bupropion also contributes its own NDRI antidepressant mechanism. The fixed combination is dextromethorphan 45 milligrams plus bupropion 105 milligrams, dosed daily for three days, then twice daily.

The clinical claim — and the trial data support it — is that improvement appears within the first week, faster than standard antidepressants. The mechanism is conceptually parallel to esketamine: NMDA antagonism producing rapid synaptogenesis. The advantage is that it's oral, daily, and does not require clinic-based administration. No REMS, no monitored observation, no dissociation requiring supervision.

Indications are major depression. Patients with treatment-resistant depression or those who failed standard agents are typical candidates, though the label is broader.

Side effects: dizziness is the most common, especially early. Headache, diarrhea, somnolence, dry mouth, sexual dysfunction. Some patients experience mild dissociative phenomena though far less than with esketamine. The bupropion component carries its own profile — modest seizure risk, activation, contraindication in eating disorders and seizure history.

Drug interaction considerations are substantial. The drug is a deliberate CYP2D6 interaction, so co-administered 2D6 substrates are affected. Combination with MAOIs is contraindicated. Combination with other strongly serotonergic agents requires caution. Other CYP2D6 inhibitors compounding the interaction are a concern.

Cost is a real-world constraint. Auvelity is brand-only, expensive, and not on most formularies as a first-line option. Prior authorization is typical. The clinical role today is in treatment-resistant depression or in patients who specifically need a rapid-onset oral option and have insurance support.

The deeper point is that designed drug-drug interactions are now a legitimate pharmacology strategy. Auvelity is not a single new molecule discovered in screening; it's two old molecules combined deliberately to produce a new pharmacokinetic effect. Expect more of this kind of design in the coming years.